Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

When transgenes shape immunity: cancer immune-gene therapy.

Bonini C, Parmiani G.

J Gene Med. 2012 Jun;14(6):384-5. doi: 10.1002/jgm.2645. No abstract available.

PMID:
22736622
2.

Cancer. Cancer immunotherapy is more than a numbers game.

Offringa R.

Science. 2006 Oct 6;314(5796):68-9. No abstract available.

PMID:
17023641
3.

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.

Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, Kallen KJ.

J Gene Med. 2012 Jun;14(6):428-39. doi: 10.1002/jgm.2605.

PMID:
22262664
4.

Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.

Delcayre A, Shu H, Le Pecq JB.

Expert Rev Anticancer Ther. 2005 Jun;5(3):537-47. Review.

PMID:
16001959
5.

mRNA Cancer Vaccines.

Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R.

Recent Results Cancer Res. 2016;209:61-85. doi: 10.1007/978-3-319-42934-2_5. Review.

PMID:
28101688
6.

T-cell responses of vaccinated cancer patients.

Coulie PG, van der Bruggen P.

Curr Opin Immunol. 2003 Apr;15(2):131-7. Review.

PMID:
12633661
7.

Development of dendritic-cell based prostate cancer vaccine.

Tjoa BA, Murphy GP.

Immunol Lett. 2000 Sep 15;74(1):87-93. Review.

PMID:
10996633
8.

KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

Skoberne M, Yewdall A, Bahjat KS, Godefroy E, Lauer P, Lemmens E, Liu W, Luckett W, Leong M, Dubensky TW, Brockstedt DG, Bhardwaj N.

J Clin Invest. 2008 Dec;118(12):3990-4001. doi: 10.1172/JCI31350. Epub 2008 Nov 6.

9.

T-cell-directed cancer vaccines: the melanoma model.

Wang E, Phan GQ, Marincola FM.

Expert Opin Biol Ther. 2001 Mar;1(2):277-90. Review.

PMID:
11727535
10.

Gene therapy: development of immunostimulatory treatments for cancer.

Gilligan MG, Knox PG, Searle PF.

Biotechnol Genet Eng Rev. 2000;17:497-529. Review. No abstract available.

PMID:
11255679
11.

Biomarkers for the development of cancer vaccines: current status.

Copier J, Whelan M, Dalgleish A.

Mol Diagn Ther. 2006;10(6):337-43. Review.

PMID:
17154650
12.

Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.

Schadendorf D, Paschen A, Sun Y.

Immunol Lett. 2000 Sep 15;74(1):67-74. Review.

PMID:
10996630
13.

DCs in lymphoma--biology and therapeutic aspects.

Schultze JL, Fiore F, von Bergwelt-Baildon M.

Cytotherapy. 2004;6(2):138-47. Review. No abstract available.

PMID:
15203990
14.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
15.

Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination.

Michiels A, Tuyaerts S, Bonehill A, Heirman C, Corthals J, Thielemans K.

Methods Mol Biol. 2008;423:155-63. doi: 10.1007/978-1-59745-194-9_10.

PMID:
18370196
16.

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.

Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.

J Immunother. 2008 Jan;31(1):101-12.

PMID:
18157017
17.

Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.

Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, Gauldie J.

Cell Immunol. 1999 Dec 15;198(2):131-8.

PMID:
10648127
19.

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, Fran├žois V, Colau D, van der Bruggen P, Neyns B, Thielemans K.

Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5.

Supplemental Content

Support Center